J.B. Chemicals & Pharmaceuticals
KKR-owned brand-led franchise with top India cardiac/chronic brands, an acquired in-licensed portfolio, and a global contract lozenge manufacturing business.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
India chronic brand-builder (Cilacar, Rantac) + global lozenge CDMO + EM branded (Russia).
India chronic brand scale-up + CDMO lozenges
Brand acquisition multiples & concentration
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| J.B. Chemicals & Pharmaceuticals | 23% | 26% | 26% | 49x |
| Eris Lifesciences | 14% | 35% | 14% | 31x |
| Ajanta Pharma | 19% | 27% | 32.3% | 36x |
| Torrent Pharmaceuticals | 25% | 32% | 27% | 68x |
| Mankind Pharma | 0% | 25% | 13.5% | 49x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • India chronic brand scale-up + CDMO lozenges underpins a 23% 5Y revenue CAGR.
- • Premium 26% EBITDA margin with 26% ROCE signals durable economics.
- • Clean balance sheet (D/E 0.10) funds growth internally.
- • Brand acquisition multiples & concentration.
- • Pricing/NLEM exposure on the domestic book can cap realisation.
- • Valuation at 49x P/E prices in continued execution — little margin for error.
J.B. Chemicals & Pharmaceuticals screens as a high-quality domestic formulations franchise. With revenue of ₹3.9K Cr growing ~23% and 26% EBITDA margins, the base case is steady compounding driven by india chronic brand scale-up + cdmo lozenges, while watching brand acquisition multiples & concentration.
Trades at 49x P/E, 28.0x EV/EBITDA and 8.5x P/B. A premium to the sector — justified only if growth and returns hold.
- 1 India IPM outperformance & chronic mix
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
FY25 segments: Domestic ~58%, International ~40% (Russia/EM), CDMO ~11%, API ~2% (overlap; normalized).